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Abstract
Background: Blockade of angiotensin II type 1 (AT1) receptors ameliorates brain inflammation, and reduces
excessive brain interleukin-1 beta (IL-1β) production and release from cortical microglia. The aim of this study was
to determine whether, in addition, AT1 receptor blockade directly attenuates IL-1β-induced inflammatory responses
in neuronal cultures.
Methods: SK-N-SH human neuroblasts and primary rat cortical neurons were pretreated with telmisartan followed
by exposure to IL-1β. Gene expression was determined by reverse transcriptase (RT)-PCR, protein expression and
kinase activation by western blotting, NADPH oxidase activity by the lucigenin method, prostaglandin E2 (PGE2)
release by enzyme immunoassay, reactive oxygen species (ROS) generation by the dichlorodihydrofluorescein
diacetate fluorescent probe assay, and peroxisome proliferator-activated receptor gamma (PPARγ) involvement was
assessed with the antagonists GW9662 and T0070907, the agonist pioglitazone and the expression of PPARγ target
genes ABCG1 and CD36.
Results: We found that SK-N-SH neuroblasts expressed AT1 but not AT2 receptor mRNA. Telmisartan reduced IL-1β-
induced cyclooxygenase-2 (COX-2) expression and PGE2 release more potently than did candesartan and losartan.
Telmisartan reduced the IL-1β-induced increase in IL-1R1 receptor and NADPH oxidase-4 (NOX-4) mRNA expression,
NADPH oxidase activity, and ROS generation, and reduced hydrogen peroxide-induced COX-2 gene expression.
Telmisartan did not modify IL-1β-induced ERK1/2 and p38 mitogen-activated protein kinase (MAPK)
phosphorylation or nuclear factor-κB activation but significantly decreased IL-1β-induced c-Jun N-terminal kinase
(JNK) and c-Jun activation. The JNK inhibitor SP600125 decreased IL-1β-induced PGE2 release with a potency similar
to that of telmisartan. The PPARγ agonist pioglitazone reduced IL-1β-induced inflammatory reaction, whereas
telmisartan did not activate PPARγ, as shown by its failure to enhance the expression of the PPARγ target genes
ABCG1 and CD36, and the inability of the PPARγ antagonists GW9662 and T0070907 to modify the effect of
telmisartan on COX-2 induction. The effect of telmisartan on IL-1β-stimulated COX-2 and IL-1R1 mRNA expression
and ROS production was replicated in primary rat cortical neurons.
Conclusions: Telmisartan directly ameliorates IL-1β-induced neuronal inflammatory response by inhibition of
oxidative stress and the JNK/c-Jun pathway. Our results support the hypothesis that AT1 receptor blockers are
directly neuroprotective, and should be considered for the treatment of inflammatory conditions of the brain.
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Neuroprotection, Oxidative stress, COX-2, PGE2 release, JNK activation, IL-1β neurotoxicity
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Background
Interleukin-1 beta (IL-1β) is a neuromodulator primarily
synthesized by microglia, with multiple physiological
roles including regulation of sleep, memory, synaptic
plasticity, and the innate immune response [1-4]. IL-1β
is also a powerful inflammatory cytokine [4]. Excessive
IL-1β production and release injures neurons, and is
considered a major factor in the development and pro-
gression of neurodegenerative disorders, stroke, brain in-
jury, and depression [5-10]. At present, there are no
effective treatments to control excessive neuroinflamma-
tion [11]. The search for novel, safe, and effective central
anti-inflammatory drugs, including those directly antag-
onizing the IL-1β-induced neuronal injury [12,13], is
therefore of major interest.
The brain renin–angiotensin system (RAS) has
emerged as a novel therapeutic target. Increased RAS
activation, leading to excessive AT1 receptor stimula-
tion, is a major factor in the development and progres-
sion of brain inflammation as a consequence of central
or systemic infection [14,15], heart failure [16], and
aging [17]. In turn, administration of AT1 receptor
blockers (ARBs) decreases brain inflammation and is
neuroprotective [18,19]. Therapeutic effects of ARBs
have been shown in rodent models of systemic inflam-
mation [15], hypertension, cerebral ischemia and stroke
[20-27], intracerebral hemorrhage [28], multiple scler-
osis [29], Parkinson’s disease (PD) [30,31], Alzheimer’s
disease (AD) [32,33], and aging [17]. The neuroprotective
effect of ARBs, as reported in rodent models, is partly
direct and not entirely dependent on its effects on car-
diovascular regulation [15,22,23,32,33]. This neuropro-
tective effect has also been shown in vitro using neuronal
cultures [15,34-36].
To further clarify the mechanisms of the direct anti-
inflammatory effects of ARBs in neuronal targets, we
studied the effects of ARBs in a well-characterized
human neuronal system widely used as an in vitro model
of neuronal injury, the SK-N-SH neuroblastoma cell line
[37,38]. In particular, we focused on telmisartan as an
ARB prototype because of its reported pleiotropic anti-
inflammatory effects as an AT1 receptor antagonist and
a peroxisome proliferator-activated receptor gamma
(PPARγ) agonist [23,32,39-41]. We investigated whether
telmisartan ameliorates the inflammatory response to
IL-1β in SK-N-SH neuroblasts and what are the
mechanisms involved in these effects, and we compared
the effects of telmisartan in SK-N-SH neuroblasts with
those in rat primary cortical neurons.
Methods
Materials and reagents
Cell-culture media and supplements were obtained from
Invitrogen (Carlsbad, CA, USA). Recombinant rat IL-1β
was purchased from R&D Systems (Minneapolis, MN,
USA). Telmisartan, losartan, CGP 42112, PD 123319,
pioglitazone, diphenyleneiodonium chloride (DPI),
SP600125, GW9662 and T0070907 were all purchased
from Sigma-Aldrich (St. Louis, MO, USA). Candesartan
was a kind gift from Astra-Zeneca (Mőlndal, Sweden).
Angiotensin II was purchased from Bachem (Torrance,
CA, USA). Primers for real-time PCR were synthesized
by BioServe (Beltsville, MD, USA). SYBR Green PCR
Master Mix for qPCR was purchased from Applied Bio-
systems (Foster City, CA, USA). The remaining reagents
for RNA isolation and reverse transcription were from
Invitrogen. Primary antibodies used for western blot
analysis were: rabbit polyclonal anti-nuclear factor-kappa
B (NF-κB)-p65 antibody (1:2000, Millipore, Billerica,
MA, USA); mouse polyclonal anti-cyclooxygenase-2
(COX-2) (1:1000, Cayman Chemical, Ann Arbor, MI,
USA); rabbit anti-phospho-p38 mitogen-activated pro-
tein kinase (MAPK) (1:1000), rabbit anti-phospho-
extracellular signal-regulated kinases (ERK)1/2 (1:1000),
rabbit anti-phospho-JNK (1:1000), rabbit anti-phospho-c
-Jun (1:1000), rabbit anti-IκB-α (1:1000), rabbit anti-β-
actin (1:1000), and rabbit anti-histone H4 (1:1000), all
from Cell Signaling Technology (Danvers, MA, USA).
Secondary horseradish peroxidase-conjugated antibodies
for western blot analysis were: donkey anti-rabbit IgG
(1:5000, Amersham BioSciences, Piscataway, NJ, USA)
and goat anti-mouse IgG (1:10,000, Jackson ImmunoRe-
search, West Grove, PA, USA). Protease inhibitor cock-
tail and SuperSignal West Dura Substrate for
chemiluminescent detection were purchased from
Thermo Fisher Scientific (Pittsburg, PA, USA). All other
chemicals were obtained from Sigma-Aldrich unless
otherwise stated.
SK-N-SH neuroblast culture
Human SK-N-SH neuroblasts were obtained from the
American Type Culture Collection (HTB-11, Rockville,
MD, USA) and grown in MEM with Earle’s salts and
HEPES, supplemented with 10 % fetal bovine serum and
100 U/ml penicillin/streptomycin. Cells were cultured at
37°C in a humidified atmosphere of 5 % CO2/95 % air
until they reached 80 % confluence, then confluent
monolayers were passaged routinely by trypsinization.
Cells between passages 3 and 10 were used in this study,
and before each experiment, they were starved overnight
in a serum-free medium.
Primary rat cortical neuron culture
All animal care and experimental procedures in the
present study were approved by the National Institute of
Mental Health Animal Care and Use Committee
(Bethesda, MD, USA). All efforts were made to minimize
the number of animals used and their suffering
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(National Institutes of Health Guide for the Care and
Use of Laboratory Animals, Publication number 80–23,
received 1996). Primary cortical neuron cultures were
obtained from fetal Sprague–Dawley rats (Charles River
Laboratories, Wilmington, MA USA) at embryonic day
18 (E18) [42]. Fetal cerebral cortices were collected and
placed in ice-cold Hank’s balanced salt solution. After
removal of the meninges, the cortices were dispersed
into the same buffer containing 0.25 % trypsin, and
digested for 15 minutes at 37°C. Trypsin digestion was
stopped by adding a two-fold volume of DMEM, supple-
mented with 10 % FBS and 0.1 mg/ml DNase I. After
gentle trituration, digested tissues were separated by
centrifugation at 200 × g for 5 minutes. The cell pellets
were resuspended in complete Neurobasal culture
medium supplemented with 2 % B27 and 0.5 mmol/l
GlutaMax. After filtration through a 70 μm cell re-
strainer (BD Falcon, Vernon Hills, IL, USA), cells were
plated at a density of 1 × 106 cells/ml onto poly-D-lysine
coated plates (Becton Dickinson and Co., Franklin Lakes,
NJ, USA). Cultures were incubated in a humidified at-
mosphere of 5 % CO2/95 % air at 37°C. Only mature
cultures (10–14 days in vitro) were used in this study.
Immunocytochemical validation with anti-microtubule-
associated protein 2 (MAP-2) antibody and 4',6-diami-
dino-2-phenylindole (DAPI) showed that more than
95 % of the cells in the culture system were neurons
(data not shown).
Drug treatment
The cells were pre-incubated for 2 hours with telmisar-
tan, candesartan, losartan, CGP 42112, PD 123319, DPI,
SP600125, pioglitazone, T0070907, GW9662, or vehicle
before exposure to IL-1β. Most of the experiments were
performed with the maximum stimulatory concentration
of 10 ng/ml IL-1β, and the exposure times were 2 hours
for ROS determination, 3 hours for RT-PCR analysis,
and 24 hours for COX-2 protein and PGE2 determina-
tions. The SK-N-SH neuroblasts were incubated with
100 μmol/l H2O2 for 3 hours to determine the protective
effect of telmisartan. Activation of MAPKs, c-Jun, and
NF-κB was determined by western blotting at various
time intervals up to 2 hours. All concentrations used
and time intervals are indicated in the figure legend for
each particular experiment. All drugs were initially pre-
pared as 1000-fold concentrated stock solutions, and
were added directly into the cell-culture medium. Telmi-
sartan, DPI, SP600125, pioglitazone, T0070907, and
GW9662 were dissolved in dimethyl sulfoxide (DMSO).
The final concentration of DMSO in experimental con-
ditions was 0.1 %. Candesartan was initially dissolved in
0.1 mol/l Na2CO3, and further diluted to stock concen-
tration with isotonic saline, at a final pH of 7.5 to 8.0.
All other drugs were dissolved in isotonic saline. Control
cells were treated with the corresponding vehicle in all
experiments.
Real-time PCR
Total RNA was isolated using TRIzol reagent followed
by purification using an RNeasy Mini Kit (Qiagen, Val-
encia, CA, USA) in accordance with the manufacturer’s
instructions. Synthesis of complementary DNA (cDNA)
was performed with 0.6 μg of total RNA and Super-
Script III first-Strand Synthesis Kit (Invitrogen, Carlsbad,
CA, USA). Quantitative real-time PCR was performed
on DNA Engine Opticon™ (MJ Research, Waltham, MA)
with SYBR Green PCR Master Mix. PCR was performed
in a 20 μl reaction mixture containing 10 μl SYBR Green
PCR Master Mix, 2 μl cDNA and 0.3 μmol/l of each pri-
mer for a specific target (Table 1). The amplification
conditions consisted of 1 denaturation/activation cycle
at 95°C for 10 minutes, followed by 40 to 45 cycles at
95°C for 15 seconds and 60°C for 60 seconds. Serial dilu-
tions of cDNA from the same source as samples were
used to obtain a standard curve. The individual targets
for each sample were quantified by determining the
cycle threshold (Ct) and by comparison with the stand-
ard curve. The relative amount of the target mRNA was
normalized to the level of GAPDH mRNA.
Western blotting
For the determination of NFκB-p65 nuclear transloca-
tion, nuclear protein extracts were prepared using Nu-
clear Extraction Kit (Pierce, Rockford, IL, USA) in
accordance with the manufacturer’s instructions. For
other proteins, the whole-cell lysates were prepared in
Tris-Glycine SDS Sample Buffer (Invitrogen). The pro-
tein extracts were separated by electrophoresis on 10 %
SDS-PAGE gels and transferred onto polyvinylidene
fluoride (PVDF) membranes. The membranes were
blocked for 1 hour and incubated overnight at 4°C with
the primary antibodies, followed by washing and expos-
ure to secondary antibodies for 1 hour at room
temperature. The membranes were exposed to Super-
Signal West Dura Substrate for chemiluminescent
detection.
Measurement of reactive oxygen species
The levels of intracellular ROS were determined by the
change in the fluorescence resulting from the oxidation of
the fluorescent probe H2DCFDA using OxiSelect™ ROS
Assay Kit (Cell Biolabs, San Diego, CA, USA) in accord-
ance with the manufacturer’s instructions. After preincu-
bation with telmisartan or DPI, the cells were loaded with
H2DCFDA for 30 minutes at 37°C and exposed to IL-1β
for an additional 2 hours. The level of fluorescence, corre-
sponding to intracellular ROS, was determined using a
plate reader (VICTOR3; Perkin-Elmer, Torrance, CA,
USA) with 485 nm excitation and 535 nm emission filters.
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Prostaglandin E2 measurement by enzyme immunoassay
PGE2 release was determined in cells culture medium by
enzyme immunoassay (EIA) (PGE2 EIA Kit; Cayman
Chemical) in accordance with the manufacturer’s
instructions.
NADPH oxidase activity assay
The lucigenin method was used to determine NADPH
oxidase activity in SK-N-SH cells. Cells were collected
by scraping, and pelleted by centrifugation at 500 × g
for 5 minutes. The pellets were resuspended and
homogenized in ice-cold buffer containing 50 mmol/l
Tris, pH 7.4, 1 mmol/l EDTA, 1 mmol/l DTT,
0.5 mmol/l phenylmethylsulfonyl fluoride (PMSF) and
1× protease inhibitor cocktail. The crude membrane
fraction was pelleted by centrifugation at 16,000 × g for
90 minutes at 4°C, and the pellets were resuspended
in 200 μl of assay buffer containing 8 mmol/l sodium
phosphate, pH 7.4, 140 mmol/l NaCl, 10 mmol/l KCl,
2 mmol/l MgCl2, 50 mmol/l triethanolamine, 1 mmol/l
DTT, and 1× protease inhibitor cocktail. The total
protein concentration was determined by the Bradford
assay and adjusted to 1 mg/ml. An aliquot (200 μl) of
protein sample (100 μg of membrane proteins) were
incubated in the presence of 5 μmol/l lucigenin and
100 μmol/l NADPH. The luminescence was monitored
at 2-minute intervals using a plate reader (VICTOR3;
Perkin-Elmer) to determine relative changes in NADPH
oxidase activity.
Ang II measurement by enzyme immunoassay
Ang II concentration in the cell-culture medium was
measured using a commercial kit (Ang II EIA Kit;
Cayman Chemical) following the manufacturer’s instruc-
tions. The limit of sensitivity of the assay was 1.5 pg/ml.
Statistical analysis
Statistical significance was determined using GraphPad
Prism 5 Software (GraphPad Software, San Diego, CA,
USA). Multiple group comparisons were performed by
one-way ANOVA followed by Newman-Keuls Post test.
Differences were considered significant at P< 0.05.
Values are expressed as the mean ± SEM.
Results
Dose response and time course of interleukin-1β-induced
neuronal inflammatory response
Incubation of SK-N-SH neuroblasts in the presence of
IL-1β induced COX-2 mRNA expression in a dose-
dependent and time-dependent manner (Figure 1A,B).
Maximum stimulation of COX-2 mRNA was obtained
with 10 ng/ml IL-1β, and it reached a peak after 3 hours
of exposure (Figure 1A and 1B). Thus, this dose of IL-1β
was selected for all subsequent experiments.
Angiotensin II receptor type 1 blockade reduces
interleukin-1β-induced cyclooxygenase-2 expression and
prostaglandin E2 release
Telmisartan, candesartan and losartan reduced IL-1β in-
duction of COX-2 mRNA with equal potency (Figure 1C).
All three ARBs dose-dependently reduced IL-1β-induced
PGE2 release, but telmisartan was significantly more po-
tent than candesartan or losartan (Figure 1D). Telmisartan
dose-dependently decreased IL-1β-induced COX-2 mRNA
expression (Figure 1E) and COX-2 protein expression
(Figure 1F).
Table 1 List of PCR primers used in the study
Gene Accession number Forward primer (5′!3′) Reverse primer (5′!3′)
hAT1 S77410 ACCGCCCCTCAGATAATGTAAG TGAAGTGCTGCAGAGGAATGTT
hCOX-2 NM_000963 GATTGCCCGACTCCCTTGG AACTGATGCGTGAAGTGCTG
hGAPDH NM_002046 CCCATCACCATCTTCCAGGAG GTTGTCATGGATGACCTTGGCC
hIκB-α NM_020529 CGGACTGCCCTTCACCTC ACATCAGCCCCACACTTCAA
hIL-1R1 NM_000877 AGAGGAAAACAAACCCACAAGG CTGGCCGGTGACATTACAGAT
hNOX-1 NM_013955 ATCACAACCTCACCTTCCAC ATAGGCTGGAGAGAATGGA
hNOX-2 NM_000397 CCCTTTGGCACTGCCAGTGAAGAT CAATCCCTGCTCCCACTAACATCA
hNOX-4 NM_016931 GGATCACAGAAGGTTCCAAGCAG GCAGCCACATGCACGCCTGAGAA
hNOX-5 NM_024505 ATCAAGCGGCCCCCTTTTTTTCAC CTCATTGTCACACTCCTCGACAGC
rAT1A NM_030985 AGCCTGCGTCTTGTTTTGAG GCTGCCCTGGCTTCTGTC
rCOX-2 AF233596 CGGAGGAGAAGTGGGGTTTAGGAT TGGGAGGCACTTGCGTTGATGG
rGAPDH NM_017008 ATGACTCTACCCACGGCAAG TGGAAGATGGTGATGGGTTT
rIL-1R1 NM_013123 TGAATGTGGCTGAAGAGCAC CTTCCATCGTCTCATTCCGT
h, human; r, rat.
For AT1 receptor mRNA expression, the products of PCR amplification were separated on 3 % agarose gel and visualized with ethidium bromide to verify the size
of amplicon.
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Figure 1 Telmisartan inhibits interleukin-1 beta (IL-1β)-induced cyclooxygenase-2 (COX-2) mRNA and protein expression and
prostaglandin E2 (PGE2) release in SK-N-SH neuroblasts (A,B) IL-1β dose-dependently and time-dependently induces COX-2 mRNA
expression in SK-N-SH neuroblasts. The cells were incubated with (A) the indicated concentrations of IL-1β for 3 hours, or with (B) 10 ng/ml
IL-1β at indicated time intervals to determine COX-2 mRNA expression. Results are expressed as fold change relative to vehicle-treated group
(Veh). (C) Telmisartan, candesartan, and losartan reduced IL-1β induced COX-2 mRNA expression with similar potency. The cells were pretreated
with 10 μmol/l telmisartan (Telm), candesartan (Cand), or losartan (Los) for 2 hours before exposure for 3 hours to 10 ng/ml IL-1β. Results are
expressed as the percentage of IL-1β. (D) Telmisartan was the most effective of AT1 receptor blockers at reducing the IL-1β-induced PGE2 release.
Cells were pretreated with indicated concentrations of Telm, Cand, or Los for 2 hours before exposure for 24 hours to 10 ng/ml IL-1β to
determine cumulative PGE2 release. Results are expressed as the percentage of IL-1β. (E,F) Telmisartan dose-dependently reduced IL-1β-induced
COX-2 mRNA and protein expression. The cells were pretreated with indicated concentrations of Telm for 2 hours, then incubated with 10 ng/ml
IL-1β for (E) 3 hours to determine COX-2 mRNA expression, or (F) 24 hours to determine COX-2 protein expression. The picture is a
representative western blot. All results are means ± SEM from at least three independent experiments. * P< 0.05, ** P< 0.01, *** P< 0.001 vs. IL-
1β; # P< 0.05, ### P< 0.001 vs. Veh; $$$ P< 0.001 vs. IL-1β+ 10 μmol Telm.
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Angiotensin II receptor types in SK-N-SH neuroblasts and
the effect of receptor blockade
SK-N-SH neuroblasts expressed AT1 receptor mRNA, and
the receptor expression was not affected by IL-1β or tel-
misartan, either alone or in a combination (Figure 2A).
AT2 receptor mRNA was not detectable in our prepar-
ation of SK-N-SH neuroblasts. Incubation in the pres-
ence of the AT2 receptor agonist CGP 42112 did not
change IL-1β stimulation of COX-2 gene expression
(Figure 2B) or PGE2 release (Figure 2C). Similarly, incu-
bation in the presence of the AT2 receptor antagonist
PD 123319 did not change IL-1β stimulation of PGE2
release, and did not alter the inhibitory effect of telmi-
sartan (Figure 2C).
Telmisartan prevents interleukin-1β-induced NADPH
oxidase activation, reactive oxygen species production
and interleukin-1 receptor 1 gene expression
High expression of the NADPH oxidase isoform NOX-4
and substantially lower expression of NOX-5 were found
in SK-N-SH neuroblasts (Figure 3A). Expression of
NOX-1 and NOX-2 was not detected (Figure 3A). Ex-






































































































Figure 2 Role of angiotensin II receptor type 1 (AT1) and type 2 (AT2) receptors in interleukin-1 beta (IL-1β)-induced neuronal
inflammatory response in SK-N-SH cells. (A) Expression of Angiotensin II AT1 receptor mRNA in SK-N-SH neuroblasts. The cells were pretreated
with 10 μmol/l telmisartan (Telm) for 2 hours before exposure for 3 hours to 10 ng/ml IL-1β. (Right) AT1 receptor expression normalized to
GAPDH mRNA. The picture shows visualized products of the RT-PCR reaction after separation on agarose gel. (B) Angiotensin II AT2 receptor
agonist CGP 42112 (CGP) does not modify IL-1β-induced COX-2 mRNA expression. The cells were pretreated with 1 μmol/l CGP 42112 for 2 hours
before exposur for 3 hourse to 10 ng/ml IL-1β. (C) Angiotensin II AT2 receptor antagonist PD 123319 or AT2 receptor agonist CGP 42112 do not
affect IL-1β-induced PGE2 release or the inhibitory effect of telmisartan. The cells were pretreated for 2 hours with 10 μmol/l PD 123319 (PD),
10 μmol/l CGP, or 10 μmol/l Telm alone or in combination with PD, before exposure for 24 hours to 10 ng/ml IL-1β to determine cumulative
PGE2 release. Results are expressed as a percentage of IL-1β. All results are means ± SEM from at least three independent experiments.
*** P< 0.001 vs. IL-1β.
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Figure 3 Telmisartan reduces interleukin-1 beta (IL-1β)-induced NADPH oxidase activation, reactive oxygen species formation and IL-1
receptor 1 (IL-1R1) mRNA expression in SK-N-SH neuroblasts. (A) Untreated SK-N-SH cells were analyzed for mRNA expression of different
NADPH oxidase isoforms. NADPH oxidase-4 (NOX-4) is the dominant isoform of NADPH oxidase in SK-N-SH neuroblasts. The picture shows
visualized products of a RT-PCR reaction after separation in an agarose gel. (B,C) Telmisartan reduced IL-1β-induced NOX-4 mRNA expression and
NADPH oxidase activity. The cells pretreated with 10 μmol/l telmisartan (Telm) for 2 hours, were incubated with 10 ng/ml IL-1β for 3 hours to
determine (B) NOX-4 mRNA expression and (C) NADPH oxidase activity. (D) Telmisartan reduced IL-1β-induced reactive oxygen species (ROS)
generation to a lesser extent than does diphenyleneiodonium (DPI). The cells were pretreated with 10 μmol/l Telm or 5 μmol/l DPI for 2 hours
before 1 hours exposure to 10 ng/ml IL-1β to determine ROS generation. (E,F) DPI dose-dependently inhibited IL-1β-induced PGE2 release with a
potency similar to telmisartan. The cells pretreated with indicated concentrations of DPI or Telm for 2 hour were incubated with IL-1β for 24
hours to determine cumulative PGE2 release. (G) Both telmisartan and DPI reduce hydrogen peroxide-induced COX-2 mRNA expression. The cells
were pretreated with 10 μmol/l Telm or 5 μmol/l DPI for 2 hours before exposure for 3 hours to 100 μmol/l hydrogen peroxide (H2O2) to
determine COX-2 mRNA expression. (H) Both telmisartan and DPI reduce IL-1β-induced expression of IL-1β receptor IL-1R1 mRNA. The cells were
pretreated with 10 μmol/l Telm or 5 μmol/l DPI for 2 hours before exposure for 3 hours to 10 ng/ml IL-1β to determine IL-1R1 mRNA expression.
Results are presented as a percentage of Veh. All results are means ± SEM from at least three independent experiments. * P< 0.05, ** P< 0.01,
*** P< 0.001 vs. IL-1β or H2O2; ### P< 0.001 vs. Veh.
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expression, and this effect was reduced by telmisartan
(Figure 3B). IL-1β significantly increased NADPH oxi-
dase activity, an effect also reduced by telmisartan
(Figure 3C). IL-1β enhanced ROS production, and this
effect was decreased by both telmisartan and DPI
(Figure 3D). DPI dose-dependently inhibited IL-1β-
induced PGE2 release (Figure 3E). The reduction in IL-
1β-stimulated PGE2 release was similar for both telmi-
sartan and DPI (Figure 3F).
Telmisartan reduced the enhanced COX-2 mRNA ex-
pression produced by H2O2 to an extent similar to that
resulting from exposure to DPI (Figure 3G).
Exposure to IL-1β enhanced mRNA expression of its
receptor, IL-1R1, and this change was reduced to a simi-
lar degree by telmisartan and DPI (Figure 3H).
Telmisartan decreases interleukin-1β-induced c-Jun
N-terminal kinase and c-Jun activation
IL-1β time-dependently activated JNK in SK-N-SH neu-
roblasts, reaching maximum stimulation after 30 to 60
minutes of exposure, and this effect was significantly
reduced by telmisartan (Figure 4A). Exposure to IL-1β
simultaneously and time-dependently enhanced c-Jun
phosphorylation, a change significantly decreased by tel-
misartan (Figure 4A). The effect of telmisartan was of
similar magnitude to that of DPI (Figure 4B). Incubation
in the presence of the specific JNK inhibitor SP600125
abrogated the IL-1β-induced phosphorylation of JNK
and c-Jun (Figure 4B), COX-2 mRNA expression
(Figure 4C), and PGE2 release, in a dose-dependent
manner (Figure 4D).
Telmisartan does not affect the interleukin-1β-stimulated
activation of p38 mitogen-activated protein kinase,
extracellular signal-regulated kinase 1/2, or nuclear
factor-κB activation
Incubation in the presence of telmisartan did not modify
IL-1β-induced p38 MAPK phosphorylation (Figure 5A)
or the ERK1/2 phosphorylation (Figure 5B). Telmisartan
did not change the time-dependent IL-1β-induced IκB-α
degradation (Figure 6A), the IκB-α mRNA expression
(Figure 6B), or the NF-κB-p65 protein nuclear transloca-
tion (Figure 6C). DPI was equally ineffective, and did
not change IL-1β-induced IκB-α mRNA expression or
the NFκB-p65 protein nuclear translocation (Figure 6B
and 6C).
Peroxisome proliferator-activated receptor-γ is not
involved in the neuroprotective effect of telmisartan
Incubation of SK-N-SH neuroblasts with the PPARγ
agonist pioglitazone significantly reduced IL-1β-induced
COX-2 mRNA expression (Figure 7A), dose-dependently
reduced PGE2 release (Figure 7B), and upregulated the
mRNA expression of the PPARγ target genes ABCG1
and CD36, without affecting PPARγ mRNA expression
(Figure 7C). Conversely, telmisartan did not alter
ABCG1 or CD36 mRNA expression (Figure 7C). Incuba-
tion of SK-N-SH neuroblasts in the presence of the
PPARγ antagonists T0070907 or GW9662 alone did not
significantly alter IL-1β-induced COX-2 mRNA expres-
sion (Figure 7D), and neither T0070907 nor GW9662
modified the inhibitory effect of telmisartan on IL-1β-
induced COX-2 mRNA and protein expression
(Figure 7D,E).
Effect of angiotensin II on the telmisartan
neuroprotection in SK-N-SH neuroblasts
Angiotensin II levels were undetectable in the cell-culture
medium (results not shown). Exposure of SK-N-SH neu-
roblasts to 1 μmol/l Ang II for 24 hours did not alter
PPARγ gene expression but strongly decreased gene ex-
pression of the PPARγ target genes ABCG1 and CD36
(Figure 8A). Pretreatment of neuroblasts with Ang II for
24 hours did not change basal COX-2 mRNA expression
or basal PGE2 release. Ang II did not affect COX-2 mRNA
expression induced by 10 ng/ml IL-1β, but did enhance
IL-1β-induced PGE2 release (Figure 8B,C). Pretreatment
with Ang II did not change the inhibitory effect of telmi-
sartan on IL-1β-stimulated COX-2 gene expression and
cumulative PGE2 release (Figure 8B,C).
(See figure on previous page.)
Figure 4 Neuroprotective effect of telmisartan is partially mediated through inhibition of the c-Jun N-terminal kinase (JNK)/c-Jun
pathway in SK-N-SH neuroblasts. (A) Telmisartan attenuated the time-dependent activation of JNK and c-Jun in response to interleukin-1 beta
(IL-1β). The cells were pretreated for 2 hours with 10 μmol/l telmisartan (Telm) before exposure to 10 ng/ml IL-1β for the indicated time intervals.
Phosphorylation of JNK and c-Jun was determined by western blotting. Representative blots are shown under the corresponding bar graphs. ###
P< 0.001 vs. Veh; * P< 0.05, *** P< 0.001 vs. corresponding IL-1β group. (B) Telmisartan inhibited IL-1β-stimulated JNK and c-Jun activation with
a potency similar to that of diphenyleneiodonium (DPI) but to a lesser extent than the JNK inhibitor SP600125. The cells were pretreated for 2
hours with 10 μmol/l Telm, 5 μmol/l DPI, or 10 μmol/l SP600125 (SP) before exposure for 30 minutes to 10 ng/ml IL-1β. The phosphorylation of
JNK and c-Jun was detected as above. Results are shown as a percentage of the IL-1β-treated group. (C,D) The JNK inhibitor SP600125 abrogated
the IL-1β-induced COX-2 mRNA expression and PGE2 release. The cells were pretreated for (C) 2 hours with 10 μmol/l SP before exposure for 3
hours to 10 ng/ml IL-1β to determine COX-2 mRNA expression, or with (D) the indicated concentrations of SP600125 before exposure for 24
hours to 10 ng/ml IL-1β to determine cumulative PGE2 release. All results are presented as means ± SEM from three independent experiments. ***
P< 0.001 vs. IL-1β; ### P< 0.001 vs. Veh; $$$ P< 0.001 vs. IL-1β+ Telm.
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Telmisartan reduces interleukin-1β upregulation of
reactive oxygen species formation, interleukin-1 receptor
type 1 and cyclooxygenase-2 mRNA expression in
primary rat cortical neurons
Exposure of primary rat cortical neurons to IL-1β
induced both COX-2 and IL-1R1 mRNA expression and
ROS generation, and these effects were significantly
reduced by telmisartan (Figure 9A-C).
Discussion
This study was designed to test the hypothesis that dir-
ect neuronal exposure to ARBs is neuroprotective. IL-1β
was selected based on its well-characterized participation
in neuronal injury associated with inflammatory and
neurodegenerative diseases of the brain [6-10]. The prin-
cipal finding of our study is that ARBs, in particular tel-
misartan, directly and significantly ameliorate the IL-1β-
induced neuronal inflammatory response.
Ang II stimulates two receptor types, the AT1 and AT2
receptors [43]. Excessive AT1 receptor stimulation is
associated with brain inflammation, whereas stimulation
of AT2 receptors has been proposed to exert balancing
neuroprotective effects, particularly when AT1 receptors
are blocked by ARB administration [43-45]. SK-N-SH
human neuroblasts expressed AT1 receptor mRNA,













h 5 15 30 60 12
0
Ve





































h 5 15 30 60 12
0
Ve























Figure 5 Telmisartan did not alter the interleukin-1 beta (IL-1β)-stimulated activation of p38 mitogen-activated protein kinase (MAPK)
or extracellular signal-regulated kinase (ERK)1/2 in SK-N-SH neuroblasts. (A,B) Cells were pretreated for 2 hours with 10 μmol/l telmisartan
(Telm) before exposure to 10 ng/ml IL-1β for the indicated time intervals. The phosphorylations of (A) p38 MAPK and (B) ERK1/2 were
determined by western blotting and normalized to the levels of β-actin. All data are presented as means ± SEM from three independent
experiments. Representative blots are shown under the corresponding bar graphs. ### P< 0.001 vs. Veh.
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cells. Furthermore, exposure of SK-N-SH neuroblasts to
PD 123319 (an AT2 receptor antagonist) or CGP 42112
(an AT2 receptor agonist) did not change the effects of
IL-1β, and PD 123319 did not modify the neuroprotec-
tive effect of telmisartan. These results indicate that the
neuroprotective effect of telmisartan and other ARBs in
SK-N-SH neuroblasts is dependent on AT1 receptor
blockade without involvement of AT2 receptors.
The neurotoxic effects of IL-1β, confirmed in this
study, have been well characterized. They depend on
stimulation of the IL-1R1 receptor, and characteristically
involve NADPH oxidase activation and ROS formation,
COX-2 induction, and PGE2 production and release,
leading to neuronal toxicity and apoptosis [5,37,38,46-
49]. Our results support the hypothesis that IL-1β, when
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Figure 6 The nuclear factor-kappa B (NF-κB) pathway is not involved in the neuroprotective effect of telmisartan in SK-N-SH
neuroblasts. (A) Telmisartan does not prevent time-dependent IκB-α protein degradation in cells in response to interleukin-1 beta (IL-1β). Cells
were pretreated for 2 hours with 10 μmol/l telmisartan (Telm) before exposure to 10 ng/ml IL-1β for the indicated time intervals. IκB-α protein
levels were determined in whole-cell extracts, and normalized to β-actin. (B) Neither telmisartan nor diphenyleneiodonium (DPI) modified IL-1β-
induced expression of IκB-α mRNA. The cells were pretreated for 2 hours with 10 μmol/l Telm or 5 μmol/l DPI before exposure for 3 hours to
10 ng/ml IL-1β to determine IκB-α mRNA expression. (C) Neither telmisartan nor DPI affected IL-1β-induced nuclear translocation of the NF-κB
p65 subunit. The cells were pretreated for 2 hours with 10 μmol/l Telm or 5 μmol/l DPI before exposure for 30 minutes to 10 ng/ml IL-1β. The
NF-κB p65 subunit protein was determined in nuclear extracts and normalized to the level of the nuclear protein histone H4. Representative
western blots are shown below the corresponding bar graphs. Results are presented as means ± SEM from three independent experiments.
# P< 0.05, ### P< 0.001 vs. Veh.
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Figure 7 (See legend on next page.)
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generate further inflammatory cascades in neurons, con-
tributing to their increased vulnerability to injury.
Telmisartan, at concentrations similar to those found
in clinical studies [50], significantly reduced the neuronal
inflammatory response induced by IL-1β. Most of the
downstream pathways activated by IL-1β in the present
study, including IL-1R1 receptor upregulation, are asso-
ciated with NADPH oxidase activation [51,52]. This
(See figure on previous page.)
Figure 7 Peroxisome proliferator-activated receptor gamma (PPARγ) activation is not involved in the neuroprotective effect of
telmisartan in SK-N-SH neuroblasts. (A,B) The PPARγ agonist pioglitazone inhibited interleukin-1 beta (IL-1β)-induced cyclooxygenase-2 (COX-
2) gene expression and prostaglandin E2 (PGE2) release. The cells were pretreated for (A) 2 hours with 10 μmol/l pioglitazone (PGZ) before
exposure for 3 hours to 10 ng/ml IL-1β to determine COX-2 mRNA expression or (B) with indicated concentrations of PGZ before exposure for 24
hours to 10 ng/ml IL-1β to determine cumulative PGE2 release. (C) Pioglitazone, but not telmisartan, induced gene expression of the PPARγ
target genes ABCG1 and CD36. The cells were incubated for 3 hours with 10 μmol/l PGZ or 10 μmol/l Telm to determine gene expression of
PPARγ and its target genes ABCG1 and CD36. Results are shown as fold change relative to the vehicle-treated group (Veh). (D,E) PPARγ
antagonists did not change the inhibitory effect of telmisartan on IL-1β-induced COX-2 expression. The cells were pretreated for 1 hour with
1 μmol/l T0070907 (T007) or 20 μmol/l GW9662 (GW), followed by 10 μmol/l Telm for 2 hours before exposure for (D) 3 hours to 10 ng/ml IL-1β
to determine COX-2 mRNA, or (E) 24 hours of IL-1β to determine COX-2 protein expression. The picture below is a representative western blot.






























































































































Figure 8 Effect of Angiotensin II (Ang II) on SK-N-SH neuroblasts. (A) Ang II did not affect peroxisome proliferator-activated receptor gamma
(PPARγ) gene expression, but strongly inhibited the expression of the PPARγ target genes ABCG1 and CD36. The cells were treated with 1 μmol/l
Ang II for 24 hours to determine PPARγ, ABCG1 and CD36 mRNA expression. # P< 0.05 vs. Veh. (B) Ang II affected neither interleukin-1 beta (IL-
1β)-induced cyclooxygenase-2 (COX-2) mRNA expression nor the inhibitory effects of telmisartan. Cells cultured for 24 hours in the presence of
1 μmol/l Ang II were pretreated for 2 hours with 10 μmol/l telmisartan (Telm) before exposure for 3 hours to 10 ng/ml IL-1β to determine COX-2
mRNA expression. Results are presented as a percentage of the IL-1β-treated group. (C) Ang II augmented IL-1β-induced PGE2 release but did not
modify the inhibitory effect of telmisartan. The cells, cultured for 24 hours in the presence of 1 μmol/l Ang II, were pretreated for 2 hours with
10 μmol/l Telm before exposure for 24 hours to 10 ng/ml IL-1β to determine cumulative PGE2 release. Results are presented as a percentage of
IL-1β. All results are means ± SEM from at least three independent experiments. *** P< 0.001.
Pang et al. Journal of Neuroinflammation 2012, 9:102 Page 13 of 19
http://www.jneuroinflammation.com/content/9/1/102
indicates that inhibition of NADPH oxidase activity by
telmisartan is a major neuroprotective mechanism.
Telmisartan decreased not only IL-1β-induced ROS
formation but also H2O2-induced COX-2 expression,
suggesting that reduction of the intracellular ROS and
ROS-related downstream pathway [10] may be import-
ant for the neuroprotective effects of telmisartan. The
wide-ranging anti-oxidant effects described here were
similar to those reported previously in non-neuronal cell
lines [53] and were of a potency similar to that of the
NADPH oxidase and NOS inhibitor DPI [54,55]. These
results are in agreement with observations showing that
ARBs decrease NADPH oxidase activation associated
with oxidative stress and neuronal apoptosis [36,56,57].
The neuroprotective effects of telmisartan were repli-
cated in rat primary cortical neurons, indicating that
they were not limited to responses only in the neuroblast
preparations.
The discovery that telmisartan significantly prevents
the IL-1β-induced upregulation of its receptor IL-1R1 in
both SK-N-SH neuroblasts and rat primary cortical neu-
rons is of major interest. Most of the IL-1β effects are
mediated by IL-1R1 receptor stimulation. Administra-
tion of IL-1R1 receptor inhibitors seems to lead to
amelioration of brain inflammation, and protection from
stroke and traumatic brain injury, thus the development
of novel IL-1R1 receptor inhibitors is the subject of ac-
tive research [12,13]. For these reasons, our finding that
telmisartan significantly prevents IL-1β induction of its
receptor indicates an additional anti-inflammatory
mechanism that might be of clinical value.
In agreement with previous observations [58], we
found that IL-1β significantly stimulates a number of
kinases, including p38 MAPK, ERK1/2, and JNK/c-Jun,
and produces a notable activation of NF-κB in human
SK-N-SH neuroblasts. Incubation in the presence of tel-
misartan significantly reduced IL-1β-induced JNK/c-Jun
activation, but had no effect on activation of p38 MAPK,
ERK1/2, and NF-κB. Stimulation of inflammatory cas-
cades is to a considerable extent the result of activation
of the transcription factor NF-κB [10]. Our observations
are therefore no unexpected and concur with those of
previous studies showing that anti-inflammatory
mechanisms are cell-specific, depending on the inflam-
matory component and on the anti-inflammatory agent
studied. In monocytes, macrophages, and microglia, NF-
κB activation seems to be a major factor leading to in-
flammation and COX-2/PGE2 production [10,41,49].
However, in brain endothelial cell lines, several import-
ant components of the IL-1β-induced inflammatory re-
sponse are independent of MAPK activity [9]. Moreover,
glucocorticoids reduce IL-1β-induced inflammation in
cells of neural origin by mechanisms independently of
NF-κB [59]. These results and our present findings indi-
cate that factors independent of NF-κB play a major role
in the anti-inflammatory effect of ARBs in neurons.
All ARBs inhibit the Ang II-induced effects associated
with stimulation of physiological AT1 receptors, but
some ARBs, particularly telmisartan, are also partial
PPARγ agonists [39,40]. Surprisingly in SK-N-SH neuro-
blasts, telmisartan failed to activate PPARγ. Further-
more, addition of PPARγ antagonists did not modify the
neuroprotective effects of telmisartan, indicating that in
these cells, AT1 receptor inhibition rather than PPARγ
activation may be the primary mechanism for the direct





























































































Figure 9 Telmisartan inhibits interleukin-1 beta (IL-1β)-induced reactive oxygen species (ROS) generation, interleukin-1 receptor type 1
(IL-1R1) and cyclooxygenase-2 (COX-2) gene expression in primary rat cortical neurons. Cells were pretreated for 2 hours with 10 μmol/l
telmisartan (Telm) before exposure for 2 hours to 1 ng/ml IL-1β to determine (A) ROS generation, and (B, C) IL-1R1 and COX-2 mRNA expression.
Results are means ± SEM from at least three independent experiments. * P< 0.05 vs. IL-1β; ## P< 0.01, ### P< 0.001 vs. Veh.
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apparently contrast with the initial demonstration of
PPARγ activation by telmisartan in cell culture [39,40],
the PPARγ-associated anti-inflammatory effects of telmi-
sartan in cultured human monocytes and THP-1 cells
[41], and the PPARγ-activating neuroprotective effects of
telmisartan shown in vivo [23,31,32].
It has been reported that although conventional
PPARγ agonists can suppress expression of pro-
inflammatory factors in primary microglia, they do not
suppress expression of pro-inflammatory molecules in
a microglial cell line expressing little or no PPARγ
[60,61], and are not neuroprotective when applied to
neurons [62]. In the SK-N-SH neuroblast preparations
used in the present study, the PPARγ gene was
expressed at relatively low levels compared with AT1
receptors (data not shown). However, in spite of the
low PPARγ gene expression, a conventional PPARγ full
agonist, pioglitazone [63], significantly activated PPARγ
in SK-N-SH neuroblasts. Conversely, under identical
experimental conditions, telmisartan was ineffective, in-
dicating that PPARγ activation is neuroprotective but is
not mediating the effects of telmisartan in SK-N-SH
neuroblasts.
Indeed, the PPARγ agonist properties of individual
ARBs seem to depend on the cell type studied and on
the conditions of the experiments. Reports from cell-
culture studies indicated that the PPARγ agonist effects
of candesartan and losartan are not high [39,40]; how-
ever, losartan has been found to increase PPARγ activa-
tion in certain cell types [64,65], and long-term
candesartan treatment upregulates PPARγ gene expres-
sion in vivo in adipose tissue [66]. Further studies are
necessary to clarify the relative contribution of AT1 re-
ceptor blockade and the PPARγ agonist activity of ARBs
in specific cell populations. Whether the PPARγ agonist
effect of ARBs may be dependent on the degree of
PPARγ gene expression remains an open question.
It is known that Ang II strongly inhibits PPARγ acti-
vation, an effect dependent on AT1 receptor stimula-
tion, and the absence of Ang II may substantially
stimulate PPARγ activity [45,67,68]. In accordance with
this, addition of a high Ang II concentration decreased
expression of PPARγ target genes in our study. How-
ever, in our studies, Ang II levels in the cell-culture
media were below the 1.5 pg/ml (corresponding to 1.5
pmol/l) limit of detection. A concentration of 1 μmol/l
of Ang II was required to produce a small increase in
the IL-1β-induced PGE2 release, whereas it did not
change COX-2 induction, had no effect on NADPH
oxidase expression or activity (data not shown), and did
not influence the protective effects of telmisartan. For
these reasons, it is very likely that in SK-N-SH neuro-
blasts, the neuroprotective effects of telmisartan are in-
dependent of Ang II-mediated stimulation of AT1
receptors. Ligand-independent AT1 receptor activation
has been reported previously in cardiomyocytes as a
consequence of mechanical stress [69].
Based on the present results, we propose that, in SK-N-
SH neuroblasts, the AT1 receptor may be constitutively ac-
tive, and the neuroprotective effects of telmisartan and
other ARBs may be the result of a decrease of such consti-
tutive AT1 receptor activity. Recently, the constitutive activ-
ity of AT1 receptor has been reported under basal
conditions in vivo even in the absence of Ang II [70].
However, there are no reports of ligand-independent acti-
vation or constitutive AT1 receptor activity in neurons, and
the hypothesis of constitutively active neuronal AT1 recep-
tors requires further confirmation.
Although it must be considered that neuronal cultures
may not be representative of in vivo conditions, the SK-
N-SH neuroblasts cultures are a good in vitro model to
study the mechanisms of action responsible for direct
ARB neuroprotection.
The present observations and those of the literature
suggest that ARBs may exert neuroprotective effects by
several associated mechanisms: decreasing inflammation-
induced circulating IL-1β levels affecting the brain and
activating microglia in brain parenchyma, by direct anti-
inflammatory effects in microglia as shown in isolated
microglia in culture [15], and by direct effects in neurons,
ameliorating the neuronal inflammatory responses pro-
duced by excess IL-1β, as reported here and illustrated in
Figure 10.
Our results have important clinical implications. IL-1β
is a strong stimulant of oxidative stress, COX-2 produc-
tion, and PGE2 release, and it has been clearly associated
with both acute and chronic inflammatory conditions of
the brain. Neuronal induction of COX-2, leading to
increased release of its product PGE2, is strongly stimu-
lated by IL-1β, and has been linked to neuroinflamma-
tory aspects of neurodegenerative diseases such as AD
and HIV-associated dementia [38,71-73]. Furthermore, it
was reported that maximal COX-2 expression predates
maximal activation of astrocytes and microglia in the
early stages of AD [74]. For this reason, the direct neu-
roprotective effects of ARBs reported here may be of
major clinical significance.
Our present observations may explain the recent find-
ings that ARB administration for the treatment of hyper-
tension significantly protects cognition, and ameliorates
the incidence and progression of AD, and that the neu-
roprotective effects of ARBs seem to be superior to
those of similarly potent anti-hypertensive medications
without direct effect on AT1 receptors [75,76]. These
clinical observations are supported by pre-clinical stud-
ies, showing that ARBs reduce NADPH oxidase activa-
tion and neuronal apoptosis and protect cognition in
animal models of AD and PD [36].
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Conclusions
Our observations highlight the pleiotropic neuroprotec-
tive effects of ARBs. As reported previously, these com-
pounds reduce the inflammation-induced production of
circulating inflammatory cytokines affecting the brain
and inflammation-induced microglial activation, signifi-
cantly diminishing inflammatory cascades. As we show
here, ARBs directly decrease the pro-inflammatory
effects of IL-1β in neurons, including reduction of IL-1β
receptor upregulation, NADPH oxidase activation, ROS
production, JNK and c-Jun activation, and pro-
inflammatory COX-2/PGE2. We propose that ARBs
may not only reduce production of excessive pro-
inflammatory factors, but also decrease neuronal vulner-
ability to injury. These properties are of significant clin-
ical value, and help to explain the increasing evidence
that treatment with ARBs ameliorates the incidence and
progression of acute and chronic neurodegenerative
conditions such as AD and stroke, in which neuroinflam-
mation plays an important role.
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Figure 10 Proposed pathways involved in the neuroprotective effects of telmisartan. The pro-inflammatory effects of interleukin-1 beta (IL-
1β) in neurons are the consequence of binding to its IL-1R1 receptor, which in turn increases NADPH oxidase activation, reactive oxygen species
(ROS) formation, c-Jun N-terminal kinase (JNK) and c-Jun activation, and IL-1 receptor 1 (IL-1R1) gene expression. This results in enhanced
expression of COX-2 and prostaglandin E2 (PGE2). Telmisartan abrogates these pro-inflammatory effects of IL-1β by mechanisms involving
inhibition of NADPH oxidase activation and the JNK/c-Jun pathway.
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